Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.
As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells.
Huang
Hong-Ying
HY
Department of Urology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.
Shariat
Shahrokh F
SF
Sun
Tung-Tien
TT
Lepor
Herbert
H
Shapiro
Ellen
E
Hsieh
Jer-Tsong
JT
Ashfaq
Raheela
R
Lotan
Yair
Y
Wu
Xue-Ru
XR
D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000503:physiopathology; D014565:Urogenital Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D019459:Urothelium / Q000378:metabolism*
D008562:Membrane Glycoproteins
J Pathol. 2003 Jan;199(1):41-9
12474225
J Cell Biol. 2002 Nov 25;159(4):685-94
12446744
Am J Surg Pathol. 2003 Jan;27(1):1-10
12502922
Toxicol Pathol. 2002 Nov-Dec;30(6):663-71
12512866
Urol Oncol. 2003 Nov-Dec;21(6):475-8
14693276
Urol Oncol. 2004 Mar-Apr;22(2):86-92
15082003
Adv Exp Med Biol. 2003;539(Pt A):33-46
15088894
Cancer Cell. 2004 Aug;6(2):111-6
15324694
J Cell Biol. 1965 Jul;26(1):25-48
5859020
Lab Invest. 1969 Aug;21(2):154-68
5804627
Cancer Res. 1977 Aug;37(8 Pt 2):2824-35
326393
J Natl Cancer Inst. 1993 Feb 3;85(3):200-6
8423624
Lancet. 1993 Aug 21;342(8869):469-71
8102431
J Biol Chem. 1994 May 6;269(18):13716-24
8175808
Am J Pathol. 1995 Nov;147(5):1383-97
7485401
J Biol Chem. 1995 Dec 15;270(50):29752-9
8530366
Eur Urol. 1998;33 Suppl 4:2-4
9615195
Am J Pathol. 1998 Dec;153(6):1957-67
9846985
Urol Int. 2004;73(3):201-8
15539837
Clin Cancer Res. 2005 May 15;11(10):3773-7
15897575
Nat Rev Cancer. 2005 Sep;5(9):713-25
16110317
J Clin Oncol. 2005 Sep 20;23(27):6533-9
16116151
Nat Rev Cancer. 2005 Nov;5(11):899-904
16327766
Neoplasia. 2005 Dec;7(12):1091-103
16354592
Urology. 2005 Dec;66(6 Suppl 1):64-74
16399416
Arch Pathol Lab Med. 2006 Jun;130(6):844-52
16740038
Am J Physiol Renal Physiol. 2006 Jul;291(1):F9-21
16609152
Hum Pathol. 2006 Dec;37(12):1568-76
16949911
J Cell Biol. 2000 Nov 27;151(5):961-72
11085999
Clin Cancer Res. 2001 Jun;7(6):1516-22
11410485
Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7
11584300
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Mol Biol Cell. 2002 Mar;13(3):830-46
11907265
Am J Med Genet. 2002 Oct 30;115(3):173-82
12407698
Mol Biol Cell. 2002 Dec;13(12):4221-30
12475947